Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial
Alexandre Mebazaa, Beth A. Davison, Ovidiu Chioncel, et al.
The Lancet (2022) Vol. 400, Iss. 10367, pp. 1938-1952
Open Access | Times Cited: 556

Showing 1-25 of 556 citing articles:

2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Theresa A. McDonagh, Marco Metra, Marianna Adamo, et al.
European Heart Journal (2023) Vol. 44, Iss. 37, pp. 3627-3639
Open Access | Times Cited: 899
2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes
Nikolaus Marx, Massimo Federici, Katharina Schütt, et al.
European Heart Journal (2023) Vol. 44, Iss. 39, pp. 4043-4140
Open Access | Times Cited: 611
2023 ACC Expert Consensus Decision Pathway on Management of Heart Failure With Preserved Ejection Fraction
M. Kittleson, Gurusher Panjrath, Kaushik Amancherla, et al.
Journal of the American College of Cardiology (2023) Vol. 81, Iss. 18, pp. 1835-1878
Open Access | Times Cited: 221
2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Theresa A. McDonagh, Marco Metra, Marianna Adamo, et al.
European Journal of Heart Failure (2024) Vol. 26, Iss. 1, pp. 5-17
Open Access | Times Cited: 158
Worsening of chronic heart failure: definition, epidemiology, management and prevention. A clinical consensus statement by the Heart Failure Association of the European Society of Cardiology
Marco Metra, Daniela Tomasoni, Marianna Adamo, et al.
European Journal of Heart Failure (2023) Vol. 25, Iss. 6, pp. 776-791
Open Access | Times Cited: 95
2024 ACC Expert Consensus Decision Pathway for Treatment of Heart Failure With Reduced Ejection Fraction
Thomas M. Maddox, James L. Januzzi, Larry A. Allen, et al.
Journal of the American College of Cardiology (2024) Vol. 83, Iss. 15, pp. 1444-1488
Closed Access | Times Cited: 63
Virtual Care Team Guided Management of Patients With Heart Failure During Hospitalization
Ankeet S. Bhatt, Anubodh S. Varshney, Alea Moscone, et al.
Journal of the American College of Cardiology (2023) Vol. 81, Iss. 17, pp. 1680-1693
Open Access | Times Cited: 41
Uptitrating Treatment After Heart Failure Hospitalization Across the Spectrum of Left Ventricular Ejection Fraction
Matteo Pagnesi, Marco Metra, Alain Cohen‐Solal, et al.
Journal of the American College of Cardiology (2023) Vol. 81, Iss. 22, pp. 2131-2144
Open Access | Times Cited: 41
NT-proBNP and high intensity care for acute heart failure: the STRONG-HF trial
Marianna Adamo, Matteo Pagnesi, Alexandre Mebazaa, et al.
European Heart Journal (2023) Vol. 44, Iss. 31, pp. 2947-2962
Open Access | Times Cited: 40
Finerenone in patients with heart failure with mildly reduced or preserved ejection fraction: Rationale and design of the FINEARTS‐HF trial
Muthiah Vaduganathan, Brian Claggett, Carolyn S.P. Lam, et al.
European Journal of Heart Failure (2024) Vol. 26, Iss. 6, pp. 1324-1333
Open Access | Times Cited: 29
2024 update in heart failure
Alberto Beghini, Antonio Maria Sammartino, Z. Papp, et al.
ESC Heart Failure (2024)
Open Access | Times Cited: 28
SGLT2 inhibitors: from glucose-lowering to cardiovascular benefits
Alberto Preda, Fabrizio Montecucco, Federico Carbone, et al.
Cardiovascular Research (2024) Vol. 120, Iss. 5, pp. 443-460
Open Access | Times Cited: 27
Contemporary pharmacological treatment and management of heart failure
Biykem Bozkurt
Nature Reviews Cardiology (2024) Vol. 21, Iss. 8, pp. 545-555
Closed Access | Times Cited: 23
Baseline characteristics of patients with heart failure with mildly reduced or preserved ejection fraction: The FINEARTS‐HF trial
Scott D. Solomon, John W. Ostrominski, Muthiah Vaduganathan, et al.
European Journal of Heart Failure (2024) Vol. 26, Iss. 6, pp. 1334-1346
Open Access | Times Cited: 21
Current Approaches to Worsening Heart Failure: Pathophysiological and Molecular Insights
Andrea D’Amato, Silvia Prosperi, Paolo Severino, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 3, pp. 1574-1574
Open Access | Times Cited: 20
Eligibility and Projected Benefits of Rapid Initiation of Quadruple Therapy for Newly Diagnosed Heart Failure
Stephen J. Greene, Iyanuoluwa Ayodele, Jacob B. Pierce, et al.
JACC Heart Failure (2024) Vol. 12, Iss. 8, pp. 1365-1377
Open Access | Times Cited: 20
Sex Disparities in Longitudinal Use and Intensification of Guideline-Directed Medical Therapy Among Patients With Newly Diagnosed Heart Failure With Reduced Ejection Fraction
Andrew Sumarsono, Luyu Xie, Neil Keshvani, et al.
Circulation (2024) Vol. 149, Iss. 7, pp. 510-520
Open Access | Times Cited: 18
Interventions for Optimization of Guideline-Directed Medical Therapy
Amber Tang, Nicholas K. Brownell, Jacob S. Roberts, et al.
JAMA Cardiology (2024) Vol. 9, Iss. 4, pp. 397-397
Closed Access | Times Cited: 17
How to tackle therapeutic inertia in heart failure with reduced ejection fraction. A scientific statement of the Heart Failure Association of the ESC
Gianluigi Savarese, Felix Lindberg, Antonio Cannatà, et al.
European Journal of Heart Failure (2024) Vol. 26, Iss. 6, pp. 1278-1297
Open Access | Times Cited: 14
Therapy duration and improvement of ventricular function in de novo heart failure: the Heart Failure Optimization study
Christian Veltmann, David Duncker, Michael Doering, et al.
European Heart Journal (2024) Vol. 45, Iss. 30, pp. 2771-2781
Open Access | Times Cited: 14
Effects of Rapid Uptitration of Neurohormonal Blockade on Effective, Sustainable Decongestion and Outcomes in STRONG-HF
Jan Biegus, Alexandre Mebazaa, Beth A. Davison, et al.
Journal of the American College of Cardiology (2024) Vol. 84, Iss. 4, pp. 323-336
Closed Access | Times Cited: 14
Pulmonary hypertension associated with left heart disease
Bradley A. Maron, Guillermo Bortman, Teresa De Marco, et al.
European Respiratory Journal (2024) Vol. 64, Iss. 4, pp. 2401344-2401344
Open Access | Times Cited: 14
Implementation of guideline‐recommended therapies in heart failure with reduced ejection fraction according to heart failure duration: An analysis of 55 581 patients from the Swedish Heart Failure (SwedeHF) Registry
Angiza Shahim, Cecilia Linde, Gianluigi Savarese, et al.
European Journal of Heart Failure (2025)
Open Access | Times Cited: 1
Sacubitril/valsartan versus valsartan initiation in patients naïve to renin–angiotensin system inhibitors: Insights from PARAGLIDE‐HF
Nina Nouhravesh, Alexander Gunn, Derek D. Cyr, et al.
European Journal of Heart Failure (2025)
Open Access | Times Cited: 1
Inpatient versus outpatient diagnosis of heart failure across the spectrum of ejection fraction: a population cohort study
Huan Wang, Chuang Gao, Magalie Guignard‐Duff, et al.
Heart (2025), pp. heartjnl-324160
Closed Access | Times Cited: 1
Page 1 - Next Page

Scroll to top